Top

Radiation Oncology

Published in:

Open Access 01-12-2019 | Magnetic Resonance Imaging | Research

Impact of regular magnetic resonance imaging follow-up after stereotactic radiotherapy to the surgical cavity in patients with one to three brain metastases

Authors: N. Bachmann, D. Leiser, E. Ermis, S. Vulcu, P. Schucht, A. Raabe, D. M. Aebersold, E. Herrmann

Published in: Radiation Oncology | Issue 1/2019

Abstract

Background

Administering stereotactic radiotherapy to the surgical cavity and thus omitting postoperative whole brain radiotherapy (WBRT) is a favored strategy in limited metastatic brain disease. Little is known about the impact of regular magnetic resonance imaging follow-up (MRI FU) in such patient cohorts. The aim of this study is to examine the impact of regular MRI FU and to report the oncological outcomes of patients with one to three brain metastases (BMs) treated with stereotactic radiosurgery (SRS) or hypo-fractionated stereotactic radiotherapy (HFSRT) to the surgical cavity.

Methods

We retrospectively analyzed patients who received SRS or HFSRT to the surgical cavity after resection of one to two BMs. Additional, non-resected BMs were managed with SRS alone. Survival was estimated by the Kaplan-Meier method. Prognostic factors were examined with the log-rank test and Cox proportional hazards model. Regular MRI FU was defined as performing a brain MRI 3 months after radiotherapy (RT) and/or performing ≥1 brain MRI per 180 days. Primary endpoint was local control (LC). Secondary endpoints were distant brain control (DBC), overall survival (OS) and the correlation between regular MRI FU and overall survival (OS), symptom-free survival (SFS), deferment of WBRT and WBRT-free survival (WFS).

Results

Overall, 75 patients were enrolled. One, 2 and 3 BMs were seen in 63 (84%), 11 (15%) and 1 (1%) patients, respectively. Forty (53%) patients underwent MRI FU 3 months after RT and 38 (51%) patients received ≥1 brain MRI per 180 days. Median OS was 19.4 months (95% CI: 13.2–25.6 months). Actuarial LC, DBC and OS at 1 year were 72% (95% CI: 60–83%), 60% (95% CI: 48–72%) and 66% (95% CI: 53–76%), respectively. A planning target volume > 15 cm³ (p = 0.01), Graded Prognostic Assessment (GPA) score (p = 0.001) and residual tumor after surgery (p = 0.008) were prognostic for decreased OS in multivariate analysis. No significant correlation between MRI FU at 3 months and OS (p = 0.462), SFS (p = 0.536), WFS (p = 0.407) or deferment of WBRT (p = 0.955) was seen. Likewise, performing ≥1 MRI per 180 days had no significant impact on OS (p = 0.954), SFS (p = 0.196), WFS (p = 0.308) or deferment of WBRT (p = 0.268).

Conclusion

Our results regarding oncological outcomes consist with the current data from the literature. Surprisingly, regular MRI FU did not result in increased OS, SFS, WFS or deferment of WBRT in our cohort consisting mainly of patients with a single and resected BM. Therefore, the impact of regular MRI FU needs prospective evaluation.

Trial registration

Project ID: 2017–00033, retrospectively registered.

Gavrilovic IT, Posner JB. Brain metastases: epidemiology and pathophysiology. J Neuro-Oncol. 2005;75:5–14. https://doi.org/10.1007/s11060-004-8093-6 .CrossRef

Nayak L, Lee EQ, Wen PY. Epidemiology of brain metastases. Curr Oncol Rep. 2012;14:48–54. https://doi.org/10.1007/s11912-011-0203-y .CrossRefPubMed

Patchell RA. The management of brain metastases. Cancer Treat Rev. 2003;29:533–40.CrossRef

Zakaria R, Das K, Bhojak M, Radon M, Walker C, Jenkinson MD. The role of magnetic resonance imaging in the management of brain metastases: diagnosis to prognosis. Cancer Imaging. 2014;14:8. https://doi.org/10.1186/1470-7330-14-8 .CrossRefPubMedPubMedCentral

Fabi A, Felici A, Metro G, Mirri A, Bria E, Telera S, et al. Brain metastases from solid tumors: disease outcome according to type of treatment and therapeutic resources of the treating center. J Exp Clin Cancer Res. 2011;30:10. https://doi.org/10.1186/1756-9966-30-10 .CrossRefPubMedPubMedCentral

Brown PD, Jaeckle K, Ballman KV, Farace E, Cerhan JH, Anderson SK, et al. Effect of radiosurgery alone vs radiosurgery with whole brain radiation therapy on cognitive function in patients with 1 to 3 brain metastases: a randomized Clinical trial. JAMA. 2016;316:401–9. https://doi.org/10.1001/jama.2016.9839 .CrossRefPubMedPubMedCentral

Kocher M, Soffietti R, Abacioglu U, Villà S, Fauchon F, Baumert BG, et al. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study. J Clin Oncol. 2011;29:134–41. https://doi.org/10.1200/JCO.2010.30.1655 .CrossRefPubMed

Brown PD, Ballman KV, Cerhan JH, Anderson SK, Carrero XW, Whitton AC, et al. Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC·3): a multicentre, randomised, controlled, phase 3 trial. Lancet Oncol. 2017;18:1049–60. https://doi.org/10.1016/S1470-2045(17)30441-2 .CrossRefPubMedPubMedCentral

Lester SC, Taksler GB, Kuremsky JG, Lucas JT, Ayala-Peacock DN, Randolph DM, et al. Clinical and economic outcomes of patients with brain metastases based on symptoms: an argument for routine brain screening of those treated with upfront radiosurgery. Cancer. 2014;120:433–41. https://doi.org/10.1002/cncr.28422 .CrossRefPubMed

10.

Hanssens P, Karlsson B, Yeo TT, Chou N, Beute G. Detection of brain micrometastases by high-resolution stereotactic magnetic resonance imaging and its impact on the timing of and risk for distant recurrences. J Neurosurg. 2011;115:499–504. https://doi.org/10.3171/2011.4.JNS101832 .CrossRefPubMed

11.

NCCN. Clinical practice guidelines in oncology. 2018. https://www.nccn.org/professionals/physician_gls/pdf/cns.pdf. Accessed 23 July 2018.

12.

Soike MH, McTyre ER, Hughes RT, Farris M, Cramer CK, LeCompte MC, et al. Initial brain metastasis velocity: does the rate at which cancers first seed the brain affect outcomes? J Neuro-Oncol. 2018. https://doi.org/10.1007/s11060-018-2888-3 .

13.

Farris M, McTyre ER, Cramer CK, Hughes R, Randolph DM, Ayala-Peacock DN, et al. Brain metastasis velocity: a novel prognostic metric predictive of overall survival and freedom from whole-brain radiation therapy after distant brain failure following upfront radiosurgery alone. Int J Radiat Oncol Biol Phys. 2017;98:131–41. https://doi.org/10.1016/j.ijrobp.2017.01.201 .CrossRefPubMed

14.

Choi CYH, Chang SD, Gibbs IC, Adler JR, Harsh GR, Lieberson RE, Soltys SG. Stereotactic radiosurgery of the postoperative resection cavity for brain metastases: prospective evaluation of target margin on tumor control. Int J Radiat Oncol Biol Phys. 2012;84:336–42. https://doi.org/10.1016/j.ijrobp.2011.12.009 .CrossRefPubMed

15.

Shaw E, Scott C, Souhami L, Dinapoli R, Kline R, Loeffler J, Farnan N. Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: final report of RTOG protocol 90-05. Int J Radiat Oncol Biol Phys. 2000;47:291–8.CrossRef

16.

Steinmann D, Maertens B, Janssen S, Werner M, Frühauf J, Nakamura M, et al. Hypofractionated stereotactic radiotherapy (hfSRT) after tumour resection of a single brain metastasis: report of a single-Centre individualized treatment approach. J Cancer Res Clin Oncol. 2012;138:1523–9. https://doi.org/10.1007/s00432-012-1227-x .CrossRefPubMed

17.

Chin LS, Regine WF, editors. Principles and practice of stereotactic radiosurgery. 2nd ed. New York: Springer New York; 2015.

18.

Patchell RA, Tibbs PA, Regine WF, Dempsey RJ, Mohiuddin M, Kryscio RJ, et al. Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. JAMA. 1998;280:1485–9.CrossRef

19.

Niwińska A, Tacikowska M, Murawska M. The effect of early detection of occult brain metastases in HER2-positive breast cancer patients on survival and cause of death. Int J Radiat Oncol Biol Phys. 2010;77:1134–9. https://doi.org/10.1016/j.ijrobp.2009.06.030 .CrossRefPubMed

20.

Gans JH, Raper DMS, Shah AH, Bregy A, Heros D, Lally BE, et al. The role of radiosurgery to the tumor bed after resection of brain metastases. Neurosurgery. 2013;72:317–25; discussion 325-6. https://doi.org/10.1227/NEU.0b013e31827fcd60 .CrossRefPubMed

21.

Ling DC, Vargo JA, Wegner RE, Flickinger JC, Burton SA, Engh J, et al. Postoperative stereotactic radiosurgery to the resection cavity for large brain metastases: Clinical outcomes, predictors of intracranial failure, and implications for optimal patient selection. Neurosurgery. 2015;76:150–6; discussion 156-7; quiz 157. https://doi.org/10.1227/NEU.0000000000000584 .CrossRefPubMed

22.

Jensen CA, Chan MD, McCoy TP, Bourland JD, deGuzman AF, Ellis TL, et al. Cavity-directed radiosurgery as adjuvant therapy after resection of a brain metastasis. J Neurosurg. 2011;114:1585–91. https://doi.org/10.3171/2010.11.JNS10939 .CrossRefPubMed

23.

Chang EL, Wefel JS, Hess KR, Allen PK, Lang FF, Kornguth DG, et al. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol. 2009;10:1037–44. https://doi.org/10.1016/S1470-2045(09)70263-3 .CrossRefPubMed

24.

Soltys SG, Adler JR, Lipani JD, Jackson PS, Choi CYH, Puataweepong P, et al. Stereotactic radiosurgery of the postoperative resection cavity for brain metastases. Int J Radiat Oncol Biol Phys. 2008;70:187–93. https://doi.org/10.1016/j.ijrobp.2007.06.068 .CrossRefPubMed

25.

Yamamoto M, Serizawa T, Shuto T, Akabane A, Higuchi Y, Kawagishi J, et al. Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective observational study. Lancet Oncol. 2014;15:387–95. https://doi.org/10.1016/S1470-2045(14)70061-0 .CrossRefPubMed

26.

Sperduto PW, Kased N, Roberge D, Xu Z, Shanley R, Luo X, et al. Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol. 2012;30:419–25. https://doi.org/10.1200/JCO.2011.38.0527 .CrossRefPubMed

27.

Brennan C, Yang TJ, Hilden P, Zhang Z, Chan K, Yamada Y, et al. A phase 2 trial of stereotactic radiosurgery boost after surgical resection for brain metastases. Int J Radiat Oncol Biol Phys. 2014;88:130–6. https://doi.org/10.1016/j.ijrobp.2013.09.051 .CrossRefPubMedPubMedCentral

28.

Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol. 1995;13:8–10. https://doi.org/10.1200/JCO.1995.13.1.8 .CrossRefPubMed

29.

Sheehan JP, Yen C-P, Nguyen J, Rainey JA, Dassoulas K, Schlesinger DJ. Timing and risk factors for new brain metastasis formation in patients initially treated only with gamma knife surgery. Clinical article. J Neurosurg. 2011;114:763–8. https://doi.org/10.3171/2010.2.JNS091539 .CrossRefPubMed

30.

Kurtz G, Zadeh G, Gingras-Hill G, Millar B-A, Laperriere NJ, Bernstein M, et al. Salvage radiosurgery for brain metastases: prognostic factors to consider in patient selection. Int J Radiat Oncol Biol Phys. 2014;88:137–42. https://doi.org/10.1016/j.ijrobp.2013.10.003 .CrossRefPubMed

31.

Lippitz B, Lindquist C, Paddick I, Peterson D, O'Neill K, Beaney R. Stereotactic radiosurgery in the treatment of brain metastases: the current evidence. Cancer Treat Rev. 2014;40:48–59. https://doi.org/10.1016/j.ctrv.2013.05.002 .CrossRefPubMed

32.

Yiu KCY, Greenspoon JN. Clinical surveillance compared with clinical and magnetic resonance imaging surveillance for brain metastasis: a feasibility survey. Curr Oncol. 2016;23:356–60. https://doi.org/10.3747/co.23.3155 .CrossRefPubMedPubMedCentral

Title: Impact of regular magnetic resonance imaging follow-up after stereotactic radiotherapy to the surgical cavity in patients with one to three brain metastases
Authors: N. Bachmann
D. Leiser
E. Ermis
S. Vulcu
P. Schucht
A. Raabe
D. M. Aebersold
E. Herrmann
Publication date: 01-12-2019
Publisher: BioMed Central
Keywords: Magnetic Resonance Imaging
Magnetic Resonance Imaging
Metastasis
Radiotherapy
Published in: Radiation Oncology / Issue 1/2019
Electronic ISSN: 1748-717X
DOI: https://doi.org/10.1186/s13014-019-1252-x

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Impact of regular magnetic resonance imaging follow-up after stereotactic radiotherapy to the surgical cavity in patients with one to three brain metastases

Abstract

Background

Methods

Results

Conclusion

Trial registration

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Trial registration

Please log in to get access to this content

Other articles of this Issue 1/2019

Palliative radiotherapy to dominant symptomatic lesion in patients with hormone refractory prostate cancer (PRADO)

Altered lymphatic drainage patterns in re-operative sentinel lymph node biopsy for ipsilateral breast tumor recurrence

Radiotherapy for small cell carcinoma of the esophagus: outcomes and prognostic factors from a retrospective study

A scoring system predicting acute radiation dermatitis in patients with head and neck cancer treated with intensity-modulated radiotherapy

Postoperative adjuvant radiation improves local control in surgically treated FIGO stage I-II small cell carcinoma of the cervix

Whole abdominopelvic intensity-modulated radiation therapy for peritoneal disseminated rhabdomyosarcoma with three-year follow-up: a case report